Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich's ataxia

Actualités

16/12/2020

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich's ataxia

Télécharger le fichier pdf

FOLLOW US

contact@kurmapartners.com

Tél: +33 (0)1 84 86 08 61

24, rue Royale
75008 Paris
France

© Copyright KURMA PARTNERS. MENTIONS LÉGALES Conditions d’utilisation INFORMATIONS RÉGLEMENTAIRES PRIVATE POLICY Design : AGENCE K2